Sanofi

Stocks

SAN

FR0000120578

Real-time Euronext Paris Other stock markets 15:08:03 22/07/2026 BST			5-day change	1st Jan Change
77.40 ^EUR	+0.85%		+1.53%	-6.40%

10:30am	SANOFI : Berenberg remains its Buy rating	ZD
07-21	Celldex to stop skin disease study after trial setback	RE

Transcript : Sanofi - Special Call

Published on 12/16/2025 at 06:20 pm GMT - Modified on 12/17/2025 at 02:50 am GMT

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Thomas Larsen (Executives)

Good afternoon and good morning, depending on where you are, and welcome to the Sanofi's first year-end late-stage pipeline review. I'm Thomas Kudsk Larsen

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Sanofi

10:30am	SANOFI : Berenberg remains its Buy rating	ZD
07-21	Celldex to stop skin disease study after trial setback	RE
07-21	Sanofi Announces Management Changes	CI
07-21	Sanofi tightens its Executive Committee
07-20	SANOFI : Gets a Neutral rating from JP Morgan	ZD
07-20	European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading	MT
07-20	Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Through IPO	MT
07-20	Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Stake Through IPO	MT
07-20	Scribe Therapeutics to Sell 7.15 Million Shares at $13-$15 Each in IPO	DJ
07-17	Sanofi strengthens its research alliance with Aqemia
07-17	Aqemia and Sanofi Expand Research Collaboration	CI
07-16	Merck gets US FDA nod for first-in-its-class oral cholesterol drug	RE
07-14	European Equities Traded in the US as American Depositary Receipts Rise Tuesday	MT
07-14	Where would AI lead Pharma in the long run?
07-14	AlphaValue/Baader Europe Downgrades Sanofi to Add, Trims PT	MT